NKTX Nkarta, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1787400 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-25.7%
TTM EPS YoY-25.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-46.6%
ROA-35.1%
ROIC (approx.)-50.0%
Asset turnover—
Leverage & solvency
Liabilities / assets30.1%
Debt / equity0.00x
Current ratio5.79x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.77x
Accruals ratio-7.9%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $0 | $0 |
| R&D expense | $90.43M | $96.74M |
| SG&A expense | $31.57M | $31.45M |
| Operating income | -$122.00M | -$128.19M |
| Income tax | $0 | $0 |
| Net income | -$104.08M | -$108.79M |
| EBITDA | -$112.80M | -$118.99M |
| EPS (basic) | -1.41 | -1.60 |
| EPS (diluted) | -1.41 | -1.60 |
| Dividends declared per share | 0.00 | 0.00 |
| Weighted avg. shares (diluted) | 73.99M | 67.87M |
| Balance sheet | ||
| Cash & equivalents | $39.63M | $27.87M |
| Short-term investments | $236.65M | $239.48M |
| Current assets | $282.51M | $273.34M |
| PP&E, net | $66.72M | $74.66M |
| Total assets | $404.21M | $501.20M |
| Current liabilities | $22.27M | $18.92M |
| Total liabilities | $91.88M | $93.23M |
| Shareholders' equity | $312.32M | $407.98M |
| Shares outstanding | 71.08M | 70.65M |
| Cash flow statement | ||
| Operating cash flow | -$88.70M | -$99.70M |
| Capital expenditure | $1.21M | $4.41M |
| Free cash flow | -$89.91M | -$104.11M |
| Investing cash flow | $100.32M | -$129.56M |
| Financing cash flow | $141,000 | $226.08M |
| Depreciation & amortization | $9.20M | $9.20M |
| Stock-based compensation | $8.56M | $16.73M |
Free plan shows the latest 2 periods; Pro shows all 7 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.